Last reviewed · How we verify
SYS6002
SYS6002 is a novel therapeutic agent in clinical development by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
At a glance
| Generic name | SYS6002 |
|---|---|
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited publicly available information exists regarding the specific mechanism of action for SYS6002. As a Phase 3 investigational drug from a Chinese pharmaceutical company, detailed mechanistic data may not yet be widely disclosed in international databases.
Approved indications
Common side effects
Key clinical trials
- SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma (PHASE2)
- A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors (PHASE1, PHASE2)
- SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (PHASE3)
- SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |